DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20160785

Clinicopathological and IHC study (estrogen receptors, progesterone receptor, HER2/NEU) in malignant ovarian tumors

Bhagyalakshmi Atla, Rema Nair Sarkar, Manasa Rasaputra

Abstract


Background: Ovarian cancer is the second most common gynaecologic malignancy, most common cause of gynaecologic cancer death and has worst prognosis among all gynecological malignancies. The clinical significance of ER and PR content in ovarian carcinomas has not been well established in the literature.

Methods: A prospective study was conducted over a period of 2 years (2013-2015) in the department of pathology, Andhra Medical College, Visakhapatnam, Andhra Pradesh, India. The study includes 42 cases of ovarian cancers. Representative 3-4μm sections were taken and IHC was performed with specific antibodies.

Results: The mean age at presentation was 39.5 years, majority of the ovarian carcinomas occurred in the age group of third and fifth decade (20/42). The commonest clinical presentation was mass per abdomen. The commonest histological type was malignant surface epithelial tumors (25/42, 59.55%) of which serous cystadenocarcinioma was the predominant tumor followed by germ cell tumors (9/42, 21.42%). Ascites was associated with higher grade and higher stage of tumors. Majority of the ovarian carcinomas were of grade 2 (57.14%) and stage 3 (35.7%).  ER was positive in (9/42) 21.42%, PR was positive in (10/42) 23.8% and Her2/neu was equivocal in (3/42) 7.14% of ovarian carcinomas. ER, PR and Her2 showed similar expression, with higher expression in cases of advanced disease.

Conclusions: The expression of steroid hormonal receptors in ovarian cancers paves way for antihormonal therapy/ targeted therapy and this requires more number of studies with larger sample size.

 


Keywords


Ovary, Carcinoma, Steroid receptors, Her2/Neu

Full Text:

PDF

References


Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: A Cancer Journal for Clinicians. 2014;64: 9-29.

Jernal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ, et al. Cancer statistics 2009. Cancer J Clin. 2009;59:225-49.

Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favourable prognostic marker in ovarian cancer. Gynecol Oncol. 2005;96(3):671-4.

Hall MJ, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol. 2003;17(5):792-803.

Garg R, Singh S, Rani R, Agarwal M, Rajvanshi R. A Clinicopathological Study of Malignant Ovarian Tumors in India. J South Asian Feder Menopause Soc. 2014:2(1):9-11.

Shilpa G, Marwah N, Chauhan G, Gupta S, Goyal R, Dahiya P, et al. Estrogen and Progesterone Receptor Expression and its Correlation with Various Clinicopathological Parameters in Ovarian Tumors. Middle East Journal of Cancer. 2014;5(2):97-103.

Sylvia MT, Kumar S, Dasari P. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables. Indian J Pathol Microbiol. 2012;55:33-7.

Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 2009;1028-35.

Hecht JL, Kotsopoulos J, Hankinson SE, Tworoger SS. Relationship between Epidemiologic Risk Factors and Hormone Receptor Expression in Ovarian Cancer: Results from the Nurses Health Study. Cancer Epidemiol Biomarkers Prev. 2009;18:1624-30.

AL- Kurtas MAM. Over expression of Her- 2 neu in ovarian surface epithelial carcinoma in a sample of Iraqi patient at Al-kindy Teaching Hospital. Al – Kindy Col Med J. 2013;9(1):126.